Infant Bacterial Therapeutics AB (publ) (“IBT”), today traded on Nasdaq First North, has applied and been approved for listing on Nasdaq First North’s Premier segment. Companies which are listed on the Premier segment generally apply the same rules as the Nasdaq Stockholm main list, which means that going forward IBT will follow the more extensive requirements. In addition, the Premier segment rules include a recommendation to follow the Swedish Code for Corporate Governance, which IBT intends to implement as of the month of March 2017.
The first day for trading on Nasdaq First North Premier is March 14, 2017. IBTs shares will continue to trade under the same ticker and ISIN code.
Staffan Strömberg, Chief Executive Officer at IBT, commented “The listing on Nasdaq First North Premier is a natural step towards the main market of Nasdaq Stockholm.”
Staffan Strömberg, CEO, phone: +46 8 410 145 55
Infant Bacterial Therapeutics AB
111 21 Stockholm
Phone: +46 8 410 145 55
Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis (“NEC”), a fatal, rare disease that afflicts premature infants. IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.
The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.
IBT is listed on Nasdaq First North with Erik Penser Bank as Certified Adviser.
This information is information that Infant Bacterial Therapeutics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13.00 CET on March 10, 2017.
See Press Release in both English and Swedish